Lakeside Holding (LSH) investor relations material

Company overview and business model

• Focuses on pharmaceutical product distribution in China, primarily through Hupan Pharmaceutical, after divesting its U.S.-based logistics business in February 2026.

• Revenue is generated from selling infusion products, specialty pharmaceuticals, and foods for special medical purposes to hospitals, distributors, and healthcare providers.

• Sales are conducted mainly through agents, with a customer base exceeding 55 in the past three quarters; five customers each accounted for over 10% of revenue.

• Evaluates opportunities for business expansion, including digital asset activities, but has not commenced such operations.

• Incorporated in Nevada in 2023, with principal executive offices in Illinois and operations in China and the Cayman Islands.

Financial performance and metrics

• Presents only two years of audited financial statements due to emerging growth company status.

• Revenue and gross profit margins are subject to fluctuations from procurement prices, bidding cycles, and government price controls.

• Profitability varies by product category, and revenue mix adjustments may offset margin pressures.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.